PreveCeutical Announces Certain Warrants Expiring on June 29, 2020
Vancouver, British Columbia--(Newsfile Corp. - June 8, 2020) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is informing its shareholders that 134,151,350 common share purchase warrants (the "Warrants") issued in connection with the Company's June 29, 2018, non-brokered private placement, including 6,301,600 finder's warrants, will expire on June 29, 2020. Each Warrant currently entitles the holder thereof to purchase one common share of...
2020-06-08 7:00 AM EDT
PreveCeutical Announces Successful Completion of its Sol-gel Program
Vancouver, British Columbia--(Newsfile Corp. - June 3, 2020) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is pleased to announce the successful completion of its Cannabinoid Sol-Gel Delivery Program (the "Sol-gel Program"). The Sol-gel Program developed and evaluated translatable formulations for the central nervous system (CNS) delivery of cannabinoid extracts ("CBDs"). Soluble gels (solgels) present an ideal platform for achieving...
2020-06-03 7:00 AM EDT
PreveCeutical Applies for Viral Prevention Program Funding
Vancouver, British Columbia--(Newsfile Corp. - June 1, 2020) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) ("PreveCeutical" or the "Company"), is pleased to inform that, in connection with its previously announced extension to its successful cannabis sol-gel program (the "Program Extension") to address the COVID-19 pandemic (News Release dated May 4, 2020), PreveCeutical was identified as a candidate to submit a preliminary application to the Strategic Innovation Fund...
2020-06-01 8:52 AM EDT
PreveCeutical Announces Debt Settlement and Conversion of Debt
Vancouver, British Columbia--(Newsfile Corp. - May 22, 2020) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical") announces that it has issued 95,600,253 common shares without par value in its capital (each, a "Share") to various arm's length creditors of the Company at a deemed issuance price of $0.023 per Share. The Company has entered into a shares for debt settlement agreement with an arm's length supplier (the "Supplier"), whereby the...
2020-05-22 5:02 PM EDT
PreveCeutical Announces Possible Viral Prevention Program Using CBD Sol-gel
Vancouver, British Columbia--(Newsfile Corp. - May 4, 2020) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) ("PreveCeutical"), is pleased to announce that it is working on an extension to its successful cannabis sol-gel program to address the COVID-19 pandemic (the "Program Extension"). The Company is not making any express or implied claims that its product has the ability to eliminate, cure or contain the COVID-19 (or SARS-2 Coronavirus) at this time. The focus of the...
2020-05-04 1:37 PM EDT
PreveCeutical Confirms its First Peptide with Promising Pre-Clinical Efficacy as a Non-Addictive Painkiller
Vancouver, British Columbia--(Newsfile Corp. - April 29, 2020) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is pleased to announce an update to its Non-Addictive Analgesic (dynorphin pain peptide) Program. Following the identification and shortlisting of a panel of peptides showing promising cell-based activity and extended stability in two distinct types of biological media, the program has identified its first peptide with clear "in...
2020-04-29 8:00 AM EDT
PreveCeutical Announces Patent Cooperation Treaty ("PCT") Application
Vancouver, British Columbia--(Newsfile Corp. - February 24, 2020) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is pleased to announce that the two Australian provisional applications entitled, "A Cyclic Peptide", which were filed last year by The University of Queensland, Australia ("UQ") have recently been combined into a single PCT application which was filed a year after the earlier priority date. This PCT application, jointly owned...
2020-02-24 8:00 AM EST
PreveCeutical Retains Patent Legal Team
Vancouver, British Columbia--(Newsfile Corp. - January 23, 2020) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical") has retained Griffith Hack as their patent attorneys. Following the successful completion of our novel designed peptides derived from Caribbean blue scorpion venom and with our two other programs coming to a close during 2020, we will need to ensure all our intellectual property is patented in order to protect its value....
2020-01-23 8:00 AM EST
PreveCeutical Announces Further Updates to the Successful Engineering & Cell-Based Efficacy Screening of its Smart-siRNA Constructs for its Dual Gene Therapy Research Program
Vancouver, British Columbia--(Newsfile Corp. - January 14, 2020) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is pleased to provide a further update on its dual gene therapy research program (the "Dual Gene Therapy Program"), an important and fundamental aspect of which involves the design, synthesis and screening of small interfering RNA ("siRNA") constructs in downregulating the gene of interest that the Company is targeting in...
2020-01-14 8:00 AM EST
PreveCeutical Announces Positive Results Following a Preliminary Safety Evaluation of Sol-Gel Formulations When Applied to Human Nasal Tissue
Vancouver, British Columbia--(Newsfile Corp. - January 8, 2020) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), announces that after successfully developing water-based cannabis extract-infused soluble gel formulations (the "CBD Sol-gel Formulations") (see news release dated July 9, 2019), the Company has now completed a preliminary safety evaluation (the "Evaluation") of selected CBD Sol-gel Formulations in freshly explanted human nasal...
2020-01-08 8:00 AM EST
PreveCeutical Announces Successful Completion from its Design, Synthesis and Preliminary Evaluation of Novel Designed Peptides Derived from Caribbean Blue Scorpion Venom in a Cell-Based Brain Cancer Model
Vancouver, British Columbia--(Newsfile Corp. - October 29, 2019) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is pleased to announce the successful completion of the design, synthesis and preliminary evaluation of key peptides from its scorpion venom-derived peptide research and development program (the "Peptide Program"). The Peptide Program is expected to enable the Company to develop their own proprietary, Nature Identical™, peptide...
2019-10-29 10:35 AM EDT
PreveCeutical Receives $616,802 AUD Research and Development Tax Incentive Cash Refund
Vancouver, British Columbia--(Newsfile Corp. - October 7, 2019) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is pleased to announce that it has received a cash refund of $616,802 AUD from the Australian Taxation Office under the Research and Development ("R&D") Tax Incentive Program. The cash refund is related to expenditures on eligible R&D activities conducted in Australia during the Company's 2018 financial year. The R&D activities...
2019-10-07 8:00 AM EDT
PreveCeutical Announces the Successful Engineering & Cell-Based Efficacy Screening of its Smart-siRNA Constructs for its Dual Gene Therapy Research Program
Vancouver, British Columbia--(Newsfile Corp. - September 23, 2019) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is pleased to provide an update on its dual gene therapy program, an important and fundamental aspect of which involves the design, synthesis and screening of small interfering RNA ("siRNA") constructs in downregulating the Company's target gene of interest, in type 2 diabetes and obesity. A panel of novel, potent siRNA...
2019-09-23 8:00 AM EDT
PreveCeutical Reaches Milestone in Research Program for Development of Non-Addictive Analgesics
Vancouver, British Columbia--(Newsfile Corp. - September 3, 2019) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is pleased to announce that it has recently reached a significant milestone in its research program for the development of non-addictive analgesics (the "Research Program") encompassing the design, synthesis and cell-based screening of lead peptide constructs intended for development as non-addictive painkilling medicines as a...
2019-09-03 8:00 AM EDT
PreveCeutical Grants Asterion Option to Purchase up to a 51% Interest in Sol-Gel Intellectual Property
Vancouver, British Columbia--(Newsfile Corp. - August 6, 2019) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) ("PreveCeutical") and Asterion Cannabis Inc. ("Asterion") announce that they have entered into an option to purchase agreement (the "Option Agreement"), whereby PreveCeutical has granted to Asterion the right and option (the "Option") to purchase up to 51% of PreveCeutical's right, title and interest in and to certain intellectual property rights relating to a...
2019-08-06 1:59 PM EDT
PreveCeutical Named in Lawsuit
Vancouver, British Columbia--(Newsfile Corp. - July 19, 2019) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), announces that it has been named as a defendant in a lawsuit commenced in the Supreme Court of British Columbia (the "Claim") on July 11, 2019 (Tietz and Loewen v. Bridgemark Financial Corp. et al.). The Claim was brought under the British Columbia Class Proceedings Act and alleges certain misrepresentations in connection with...
2019-07-19 7:45 PM EDT
PreveCeutical Successfully Incorporates Medicinal Cannabis Extracts into the Sol-Gel Drug Delivery System
Vancouver, British Columbia--(Newsfile Corp. - July 9, 2019) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), announces that it has completed the second phase of its soluble gel ("Sol-gel") drug delivery research and development program (the "Sol-gel Program"), by successfully developing formulations for cannabis extract-infused Sol-gel
2019-07-09 8:00 AM EDT
PreveCeutical Announces Appointment of New Directors
Vancouver, British Columbia--(Newsfile Corp. - June 21, 2019) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is pleased to announce the appointments of Keith Anderson and Mark Lotz to the board of directors of the Company (the "Board"), effective immediately. Stephen Van Deventer, PreveCeutical's Chief Executive Officer, commented: "Keith and Mark are experienced board members with extensive public sector experience and we are confident...
2019-06-21 11:08 AM EDT
PreveCeutical Announces Further Positive Results from its Dual Gene Therapy Research Program
Vancouver, British Columbia--(Newsfile Corp. - June 17, 2019) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is pleased to provide positive results from research conducted for its dual gene therapy research program (the "Program"). PreveCeutical previously identified four or more novel siRNA constructs, each of which preferentially targeted the gene of interest while reducing the gene's expression by no less than 80% compared to a random...
2019-06-17 8:00 AM EDT
PreveCeutical Secures $300,000 Loan and Resignation of a Director
Vancouver, British Columbia--(Newsfile Corp. - June 3, 2019) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical") announces that it has received a loan in the aggregate amount of $300,000 (the "Loan") pursuant to a loan agreement with the Company's Chairman and Chief Executive Officer, Mr. Stephen Van Deventer (the "Lender"). Loan Details The Loan has a one-year term and will bear interest at a rate of 5% per annum, compounded semi-annually and...
2019-06-03 8:00 AM EDT